Valsartan-d9 – 1 mg

Brand:
Cayman
CAS:
1089736-73-1
Storage:
-20
UN-No:
- /

Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan (Item No. 14178) by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).{21001} It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro.{20999} In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.{42153} Formulations containing valsartan have been used in the treatment of hypertension and heart failure.{13660,20999,12999}  

 

Available on backorder

SKU: 25226 - 1 mg Category:

Description

An internal standard for the quantification of valsartan by GC- or LC-MS


Formal name: N-(1-oxopentyl-2,2,3,3,4,4,5,5,5-d9)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine

Synonyms:  CGP 48933-d9

Molecular weight: 444.6

CAS: 1089736-73-1

Purity: ≥99% deuterated forms (d1-d9)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Heart Failure||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes